Madrigal Pharmaceuticals
MDGL
53 hedge funds and large institutions have $120M invested in Madrigal Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 6 closing their positions.
261% more capital invested
Capital invested by funds: $33.3M → $120M (+$87M)
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
26% more funds holding
Funds holding: 42 → 53 (+11)
4.56% more ownership
Funds ownership: 16.82% → 21.39% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.4M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$1.87M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
+$1.38M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.2M |
| 5 |
Renaissance Technologies
New York
|
+$971K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$4.96M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.87M |
| 3 |
AC
Armistice Capital
New York
|
-$1.31M |
| 4 |
Citigroup
New York
|
-$185K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$64K |
MDGL Hedge Fund Activity: Q3 2017 in Review
53 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2017, worth a combined $120M — up 261% from $33.3M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new MDGL positions and 6 closed out — a net gain of 11 holders — while 15 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $10.4M. The largest seller was Rock Springs Capital Management, cutting an estimated $4.96M.
- 53 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2017, up from 42 in Q2 2017.
- Funds reported $120M of Madrigal Pharmaceuticals stock for Q3 2017, up 261% quarter-over-quarter.
- 17 funds opened new Madrigal Pharmaceuticals positions in Q3 2017 and 6 closed out, a net change of +11 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2017 was Fidelity Investments, an estimated $10.4M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2017 was Rock Springs Capital Management, an estimated $4.96M sold.
Based on aggregated 13F filings for Q3 2017.